Brief Informant Screening Test for Mild Cognitive Impairment and Early Alzheimer’s Disease

2006 ◽  
Vol 21 (5-6) ◽  
pp. 392-402 ◽  
Author(s):  
Minglei Li ◽  
Tze Pin Ng ◽  
Ee Heok Kua ◽  
Soo Meng Ko
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Screening Test ◽  
Early Alzheimer’S Disease

Rates of progression in mild cognitive impairment and early Alzheimer's disease

Neurology ◽  
2002 ◽  
Vol 59 (7) ◽  
pp. 1034-1041 ◽  
Author(s):  
M. Storandt ◽  
E. A. Grant ◽  
J. P. Miller ◽  
J. C. Morris
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Early Alzheimer’S Disease

scholarly journals Studies of implicit prototype extraction in patients with mild cognitive impairment and early Alzheimer's disease.

2012 ◽  
Vol 38 (4) ◽  
pp. 860-880 ◽  
Author(s):  
Robert M. Nosofsky ◽  
Stephen E. Denton ◽  
Safa R. Zaki ◽  
Anne F. Murphy-Knudsen ◽  
Frederick W. Unverzagt
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Early Alzheimer’S Disease

Diagnostic utility of sound naming in early Alzheimer’s disease

2009 ◽  
Vol 15 (2) ◽  
pp. 231-238 ◽  
Author(s):  
HYEON-AE JEON ◽  
KYOUNG-MIN LEE
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Picture Naming ◽  
Temporal Cortex ◽  
Cognitive Domain ◽  
Diagnostic Utility ◽  
Future Studies ◽  
Early Alzheimer’S Disease

AbstractWhile it is well known that picture naming (PN) is impaired in Alzheimer’s disease (AD), sound naming (SN) has not been thoroughly investigated. We postulated that SN might be impaired more severely and earlier than PN, given the early involvement of the temporal cortex by AD-related pathology. SN and PN were assessed in 21 normal participants, 40 patients with mild cognitive impairment (MCI), and 27 patients in early stages of AD. Our results showed that SN accuracy and latency were more sensitive to advancing pathology in AD than PN accuracy and latency. SN was more useful and specific in distinguishing MCI patients from normal participants and therefore in potentially identifying the subset of MCI patients who already have impairment in more than one cognitive domain and may actually have incipient AD. These findings indicate a potential diagnostic utility of SN for early detection of the disease. Furthermore, even though most AD patients demonstrated more or less comparable impairment in both tasks, some were disproportionately impaired on SN and others were differentially impaired on PN. Future studies may be able to show that these discrepant groups correspond to patients with right and left hemisphere predominant AD, respectively. (JINS, 2009, 15, 231–238.)

scholarly journals Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease

Brain ◽  
2020 ◽  
Vol 143 (11) ◽  
pp. 3234-3241 ◽  
Author(s):  
Niklas Mattsson-Carlgren ◽  
Shorena Janelidze ◽  
Sebastian Palmqvist ◽  
Nicholas Cullen ◽  
Anna L Svenningsson ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Amyloid Β ◽  
Linear Mixed Effects ◽  
Three Samples ◽  
Longitudinal Plasma ◽  
Early Alzheimer’S Disease ◽  
Alzheimer’S Disease Dementia

Abstract Plasma levels of tau phosphorylated at threonine-217 (p-tau217) is a candidate tool to monitor Alzheimer’s disease. We studied 150 cognitively unimpaired participants and 100 patients with mild cognitive impairment in the Swedish BioFINDER study. P-tau217 was measured repeatedly for up to 6 years (median three samples per person, median time from first to last sample, 4.3 years). Preclinical (amyloid-β-positive cognitively unimpaired, n = 62) and prodromal (amyloid-β-positive mild cognitive impairment, n = 49) Alzheimer’s disease had accelerated p-tau217 compared to amyloid-β-negative cognitively unimpaired (β  =  0.56, P < 0.001, using linear mixed effects models) and amyloid-β-negative mild cognitive impairment patients (β  =  0.67, P < 0.001), respectively. Mild cognitive impairment patients who later converted to Alzheimer’s disease dementia (n = 40) had accelerated p-tau217 compared to other mild cognitive impairment patients (β  =  0.79, P < 0.001). P-tau217 did not change in amyloid-β-negative participants, or in patients with mild cognitive impairment who did not convert to Alzheimer’s disease dementia. For 80% power, 109 participants per arm were required to observe a slope reduction in amyloid-β-positive cognitively unimpaired (71 participants per arm in amyloid-β-positive mild cognitive impairment). Longitudinal increases in p-tau217 correlated with longitudinal worsening of cognition and brain atrophy. In summary, plasma p-tau217 increases during early Alzheimer’s disease and can be used to monitor disease progression.

Sign in / Sign up

Export Citation Format

Share Document